Early functional changes and plasma GFAP in Swedish families with Autosomal Dominant Alzheimer’s disease mutations

Read full text
Authors: Emma Susanne Luckett, Mariola Zapater‐Fajarí, Ove Almkvist, Charlotte Johansson, Konstantinos Chiotis, Marco Bucci, Anders E. Wall, Nicholas James Ashton, Kaj Blennow, Henrik Zetterberg, Elena Rodriguez‐Vieitez, Caroline Graff
+1 more Agneta K. Nordberg
Cited by: 0
References: 52

Abstract

We aimed to understand longitudinal associations between Alzheimer's disease (AD) biomarkers in Autosomal Dominant AD (ADAD) across estimated years to symptom onset (EYO). Forty-five individuals (19 mutation carriers [EYO = -7.9 ± 11.7 years, APP N = 11; PSEN1 N = 8]) from Swedish ADAD families participated. All received baseline 18F-Flurodeoxyglucose (FDG) PET and cognitive testing, and a subset (N = 26) plasma glial fibrillary acidic protein (GFAP) measurement. Follow-up data collection (including 106 FDG scans) was performed over 7.4 ± 6.4 years (visits ranged from 1-5, EYO = -25.8 to +10.3 years in mutation carriers). Mixed effects models were applied to determine longitudinal associations. APP and PSEN1 mutation carriers showed different FDG uptake profiles from EYO = -20 to -10 years, with a hypermetabolism before hypometabolism in PSEN1 mutation carriers. Early increases in plasma GFAP were primarily related to subcortical FDG decreases and cognitive changes in APP mutation carriers compared to non-carriers. We provide evidence for gene-dependent biomarker trajectories in ADAD.

Fields of Study & Subjects

Dementia and Cognitive Impairment Research Alzheimer's disease research and treatments Amyotrophic Lateral Sclerosis Research

Publication details

Journal / source
Translational Psychiatry
Volume
16
Issue
1
Pages
67–67
Publication date
27 January 2026
Language
EN